What is the level of liabilities of CRISPR Therapeutics this year?
CRISPR Therapeutics has a debt balance of 346.77 M USD this year.
In 2024, CRISPR Therapeutics's total liabilities amounted to 346.77 M USD, a -5.67% difference from the 367.6 M USD total liabilities in the previous year.
CRISPR Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating CRISPR Therapeutics's financial stability, operational efficiency, and long-term viability.
By comparing CRISPR Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
CRISPR Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in CRISPR Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
CRISPR Therapeutics has a debt balance of 346.77 M USD this year.
The liabilities of CRISPR Therapeutics have increased by -5.67% dropped compared to the previous year.
High liabilities can pose a risk for investors of CRISPR Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that CRISPR Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of CRISPR Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of CRISPR Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of CRISPR Therapeutics include investments, acquisitions, operating costs, and sales development.
The liabilities of CRISPR Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, CRISPR Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, CRISPR Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CRISPR Therapeutics is expected to pay a dividend of 0 USD.
The current dividend yield of CRISPR Therapeutics is .
CRISPR Therapeutics pays a quarterly dividend. This is distributed in the months of .
CRISPR Therapeutics paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
CRISPR Therapeutics is assigned to the 'Health' sector.
To receive the latest dividend of CRISPR Therapeutics from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.
The last dividend was paid out on 11/5/2024.
In the year 2023, CRISPR Therapeutics distributed 0 USD as dividends.
The dividends of CRISPR Therapeutics are distributed in USD.
Our stock analysis for CRISPR Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CRISPR Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.